solabegron

GW-427353 is the (R)-isomer;

Also Known As:

(R)-3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid; 3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid; GW 427353; GW-427353; GW427353; solabegron hydrochloride

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Michel, Martin C: 3 articles (05/2016 - 11/2012)
2.	Gravas, Stavros: 1 article (05/2016)
3.	Antosh, Danielle: 1 article (01/2016)
4.	Balk, Ethan M: 1 article (01/2016)
5.	Chen, Chi Chiung Grace: 1 article (01/2016)
6.	El-Nashar, Sherif: 1 article (01/2016)
7.	Gleason, Jon: 1 article (01/2016)
8.	Grimes, Cara L: 1 article (01/2016)
9.	Kim-Fine, Shunaha: 1 article (01/2016)
10.	McFadden, Brook: 1 article (01/2016)

Related Diseases

1.	Overactive Urinary Bladder (Overactive Bladder) 11/01/2012 - "A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder." 11/01/2012 - "To evaluate the efficacy and tolerability of the highly selective and potent β3-adrenoceptor agonist solabegron in a clinical proof-of-concept study in incontinent women with overactive bladder (OAB). " 05/01/2016 - "We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. " 03/01/2015 - "Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder." 03/01/2013 - "β(3)-Adrenoceptor agonists are an emerging drug class for the treatment of the overactive bladder syndrome, and clinical proof-of-concept data have been obtained for three representatives of this class, mirabegron, ritobegron, and solabegron. "
2.	Nocturia 01/01/2016 - "Mirabegron improves daily incontinence episodes, nocturia, number of daily voids, and urine volume per void, whereas solabegron improves daily incontinence episodes. "
3.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/01/2010 - "The action of GW427353 may be the neurophysiologic correlate of its beneficial effect in patients with irritable bowel syndrome."
4.	Hypertension (High Blood Pressure) 05/01/2016 - "Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo. "
5.	Constipation 05/01/2016 - "Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo. "

Related Drugs and Biologics

1.	mirabegron
2.	Adrenergic Receptors (Adrenergic Receptor)
3.	ritobegron